Ayala Pharmaceuticals General and Administrative Expenses 2011-2026 | AYLA

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Ayala Pharmaceuticals

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
1.53 M	1.59 M	7.37 M	4.34 M	3.29 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
7.37 M	1.53 M	3.62 M

Quarterly General and Administrative Expenses Ayala Pharmaceuticals

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	2.88 M	2.26 M	2.44 M	-	2.2 M	2.54 M	2.3 M	-	1.86 M	1.55 M	1.31 M	-	945 K	1.02 M	848 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
2.88 M	848 K	1.85 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
Burford Capital Limited BUR	99.3 M	$ 4.81	2.02 %	$ 761 M	Britain
Cabaletta Bio CABA	29.6 M	$ 3.37	3.45 %	$ 339 M	USA
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Can-Fite BioPharma Ltd. CANF	3.66 M	$ 3.2	4.75 %	$ 5.27 M	Israel
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Alnylam Pharmaceuticals ALNY	1.21 B	$ 334.86	-1.34 %	$ 43.9 B	USA
I-Mab IMAB	900 M	-	-	$ 866 M	China
Alterity Therapeutics Limited ATHE	5.51 M	$ 3.73	3.04 %	$ 8.97 B	Australia
AlloVir ALVR	11 M	-	4.14 %	$ 49.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Aligos Therapeutics ALGS	20.7 M	$ 7.36	-15.79 %	$ 72.8 M	USA
Esperion Therapeutics ESPR	166 M	$ 2.08	1.22 %	$ 432 M	USA
Evogene Ltd. EVGN	7.25 M	$ 0.86	4.76 %	$ 27.9 M	Israel
Allakos ALLK	45.1 M	-	-	$ 28.6 M	USA
Forte Biosciences FBRX	12.4 M	$ 31.11	-4.04 %	$ 403 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
Applied Therapeutics APLT	20.6 M	-	-	$ 8.42 M	USA
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA
Galapagos NV GLPG	141 M	$ 29.11	0.8 %	$ 2.69 B	Belgium
Genmab A/S GMAB	661 M	$ 29.26	0.67 %	$ 18.8 B	Danmark
GT Biopharma GTBP	8.95 M	$ 0.38	-1.83 %	$ 2.1 M	USA
Amphastar Pharmaceuticals AMPH	85.9 M	$ 21.69	1.45 %	$ 1.01 B	USA
Harmony Biosciences Holdings HRMY	153 M	$ 29.22	-0.24 %	$ 1.68 B	USA
BioNTech SE BNTX	286 M	$ 99.83	1.44 %	$ 27.2 B	Germany
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
ImmuCell Corporation ICCC	3.2 M	$ 7.64	-1.18 %	$ 69 M	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
InflaRx N.V. IFRX	12 M	$ 1.21	6.14 %	$ 152 M	Germany
AgeX Therapeutics AGE	11 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	107 M	$ 1.54	-1.23 %	$ 396 M	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
Immatics N.V. IMTX	33.8 M	$ 10.97	0.18 %	$ 690 M	Germany
Aquestive Therapeutics AQST	79.8 M	$ 4.19	1.07 %	$ 448 M	USA
Arcutis Biotherapeutics ARQT	275 M	$ 24.26	-3.31 %	$ 3.09 B	USA
Incyte Corporation INCY	1.38 B	$ 97.7	0.01 %	$ 19.1 B	USA
Brainstorm Cell Therapeutics BCLI	5.78 M	-	-2.5 %	$ 5.88 M	USA
AIkido Pharma AIKI	23.8 M	-	1.93 %	$ 17.4 M	USA
Innate Pharma S.A. IPHA	25.5 M	$ 1.66	1.57 %	$ 235 M	France
BioDelivery Sciences International BDSI	106 M	-	-4.8 %	$ 255 M	USA
Autolus Therapeutics plc AUTL	132 M	$ 1.48	-0.34 %	$ 394 M	Britain
Aptose Biosciences APTO	13.4 M	-	-45.71 %	$ 1.2 M	Canada
BeiGene, Ltd. BGNE	2.08 B	-	0.49 %	$ 251 B	Cayman-islands